Literature DB >> 19651608

CT-X antigen expression in human breast cancer.

Anita Grigoriadis1, Otavia L Caballero, Keith S Hoek, Leonard da Silva, Yao-Tseng Chen, Sandra J Shin, Achim A Jungbluth, Lance D Miller, David Clouston, Jonathan Cebon, Lloyd J Old, Sunil R Lakhani, Andrew J G Simpson, A Munro Neville.   

Abstract

Cancer/testis (CT) genes are predominantly expressed in human germ line cells, but not somatic tissues, and frequently become activated in different cancer types. Several CT antigens have already proved to be useful biomarkers and are promising targets for therapeutic cancer vaccines. The aim of the present study was to investigate the expression of CT antigens in breast cancer. Using previously generated massively parallel signature sequencing (MPSS) data, together with 9 publicly available gene expression datasets, the expression pattern of CT antigens located on the X chromosome (CT-X) was interrogated. Whereas a minority of unselected breast cancers was found to contain CT-X transcripts, a significantly higher expression frequency was detected in estrogen and progesterone receptor (ER) negative breast cancer cell lines and primary breast carcinomas. A coordinated pattern of CT-X antigen expression was observed, with MAGEA and NY-ESO-1/CTAG1B being the most prevalent antigens. Immunohistochemical staining confirmed the correlation of CT-X antigen expression and ER negativity in breast tumors and demonstrated a trend for their coexpression with basal cell markers. Because of the limited therapeutic options for ER-negative breast cancers, vaccines based on CT-X antigens might prove to be useful.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19651608      PMCID: PMC2716388          DOI: 10.1073/pnas.0906840106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Controlling the false discovery rate in behavior genetics research.

Authors:  Y Benjamini; D Drai; G Elmer; N Kafkafi; I Golani
Journal:  Behav Brain Res       Date:  2001-11-01       Impact factor: 3.332

Review 2.  Aromatase inhibitors for breast cancer: proven efficacy across the spectrum of disease.

Authors:  Christina I Herold; Kimberly L Blackwell
Journal:  Clin Breast Cancer       Date:  2008-02       Impact factor: 3.225

3.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

4.  Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.

Authors:  I H Park; J Ro; K S Lee; B H Nam; Y Kwon; K H Shin
Journal:  Ann Oncol       Date:  2008-07-29       Impact factor: 32.976

5.  The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Authors:  Linda C Benavides; Jeremy D Gates; Mark G Carmichael; Ritesh Patil; Ritesh Patel; Jarrod P Holmes; Matthew T Hueman; Elizabeth A Mittendorf; Dianna Craig; Alexander Stojadinovic; Sathibalan Ponniah; George E Peoples
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

6.  Genome-wide analysis of cancer/testis gene expression.

Authors:  Oliver Hofmann; Otavia L Caballero; Brian J Stevenson; Yao-Tseng Chen; Tzeela Cohen; Ramon Chua; Christopher A Maher; Sumir Panji; Ulf Schaefer; Adele Kruger; Minna Lehvaslaiho; Piero Carninci; Yoshihide Hayashizaki; C Victor Jongeneel; Andrew J G Simpson; Lloyd J Old; Winston Hide
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

Review 7.  Cancer/testis antigens: an expanding family of targets for cancer immunotherapy.

Authors:  Matthew J Scanlan; Ali O Gure; Achim A Jungbluth; Lloyd J Old; Yao-Tseng Chen
Journal:  Immunol Rev       Date:  2002-10       Impact factor: 12.988

8.  A gene-expression signature as a predictor of survival in breast cancer.

Authors:  Marc J van de Vijver; Yudong D He; Laura J van't Veer; Hongyue Dai; Augustinus A M Hart; Dorien W Voskuil; George J Schreiber; Johannes L Peterse; Chris Roberts; Matthew J Marton; Mark Parrish; Douwe Atsma; Anke Witteveen; Annuska Glas; Leonie Delahaye; Tony van der Velde; Harry Bartelink; Sjoerd Rodenhuis; Emiel T Rutgers; Stephen H Friend; René Bernards
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

Review 9.  Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review.

Authors:  Yolanda Madarnas; Maureen Trudeau; Jacob A Franek; David McCready; Kathleen I Pritchard; Hans Messersmith
Journal:  Cancer Treat Rev       Date:  2008-05-27       Impact factor: 12.111

10.  CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens.

Authors:  Luiz Gonzaga Almeida; Noboru J Sakabe; Alice R deOliveira; Maria Cristina C Silva; Alex S Mundstein; Tzeela Cohen; Yao-Tseng Chen; Ramon Chua; Sita Gurung; Sacha Gnjatic; Achim A Jungbluth; Otávia L Caballero; Amos Bairoch; Eva Kiesler; Sarah L White; Andrew J G Simpson; Lloyd J Old; Anamaria A Camargo; Ana Tereza R Vasconcelos
Journal:  Nucleic Acids Res       Date:  2008-10-05       Impact factor: 16.971

View more
  53 in total

1.  Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers.

Authors:  Jun Yao; Otavia L Caballero; W K Alfred Yung; John N Weinstein; Gregory J Riggins; Robert L Strausberg; Qi Zhao
Journal:  Cancer Immunol Res       Date:  2013-11-25       Impact factor: 11.151

2.  Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways.

Authors:  Stine Ninel Hansen; David Westergaard; Mathilde Borg Houlberg Thomsen; Mette Vistesen; Khoa Nguyen Do; Louise Fogh; Kirstine C Belling; Jun Wang; Huanming Yang; Ramneek Gupta; Henrik J Ditzel; José Moreira; Nils Brünner; Jan Stenvang; Anne-Sofie Schrohl
Journal:  Tumour Biol       Date:  2015-01-18

3.  The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy.

Authors:  Laurence M Wood; Zhen-Kun Pan; Matthew M Seavey; Geetha Muthukumaran; Yvonne Paterson
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

Review 4.  Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer.

Authors:  Takumi Shiraishi; Robert H Getzenberg; Prakash Kulkarni
Journal:  Asian J Androl       Date:  2012-02-20       Impact factor: 3.285

5.  High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer.

Authors:  Tanja Badovinac Črnjević; Badovinac Črnjević Tanja; Giulio Spagnoli; Spagnoli Giulio; Antonio Juretić; Juretić Antonio; Jasminka Jakić-Razumović; Jakić-Razumović Jasminka; Paula Podolski; Podolski Paula; Nera Šarić; Šarić Nera
Journal:  Med Oncol       Date:  2011-11-25       Impact factor: 3.064

6.  Differential proteomic analysis of pathway biomarkers in human breast cancer by integrated bioinformatics.

Authors:  Liu Fu-Jun; Jin Shao-Hua; Shen Xiao-Fang
Journal:  Oncol Lett       Date:  2012-08-24       Impact factor: 2.967

7.  The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein.

Authors:  Yu Zeng; Yanan He; Fan Yang; Steven M Mooney; Robert H Getzenberg; John Orban; Prakash Kulkarni
Journal:  J Biol Chem       Date:  2011-02-25       Impact factor: 5.157

8.  Expression of cancer/testis antigens in prostate cancer is associated with disease progression.

Authors:  Takahito Suyama; Takumi Shiraishi; Yu Zeng; Wayne Yu; Nehal Parekh; Robert L Vessella; Jun Luo; Robert H Getzenberg; Prakash Kulkarni
Journal:  Prostate       Date:  2010-12-01       Impact factor: 4.104

9.  Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines.

Authors:  Annika N Alexopoulou; Maria Leao; Otavia L Caballero; Leonard Da Silva; Lynne Reid; Sunil R Lakhani; Andrew J Simpson; John F Marshall; A Munro Neville; Parmjit S Jat
Journal:  Breast Cancer Res       Date:  2010-07-19       Impact factor: 6.466

10.  Autoantibodies to tumor-associated antigens in breast carcinoma.

Authors:  Ettie Piura; Benjamin Piura
Journal:  J Oncol       Date:  2010-11-21       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.